Tracking and Translating the Field

Bridging the scientific field and communities where research happens

We track and translate complex science, funding and policy decisions, community advocacy and more, to make it accessible, give context, identify gaps and opportunities for advocacy and ensure community priorities are at the center of global health. 

HIV prevention research and development is accelerating, with more options available than ever before. But progress toward crucial targets to end the epidemic and prepare for future ones has been far too slow. New leadership, research, and commitments at the global, national, and local levels bring power and potential to strengthen and advance HIV prevention and global health equity, however, but we need to ensure that new policies and product access initiatives are inclusive and donors and decision makers are accountable. 

AVAC tracks important issues, in research, policy, financing, news headlines and more. With colleagues and partners, we analyze the data, issues, policy and perspectives, and we translate it into useful and usable resources that all can use to inform their work. We do this by: 

  • developing and sharing communications, reports and materials that provide accessible, up-to-date resources on the full spectrum of biomedical HIV prevention products from research to rollout and real-time analysis of emerging developments; 
  • keeping pace with and widely sharing information on emerging developments in the field of HIV prevention research through various databases and accessible online platforms; 
  • promoting informed decision making, evidence-based advocacy and awareness raising around timely issues in HIV prevention research and product development, as well as integration with other related areas of health; and
  • convening conversations, meetings, and workshops with various stakeholders to share complex science to ensure that communities, advocates, and decision makers have clear, accurate, equitable, and timely access to information to strengthen evidence-based advocacy, policies, and programs.

The Latest on Tracking and Translating the Field

Infographic

An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible

The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.

Infographic

PrEP Delivery Imperiled

Programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health. This graphic illustrates some of the severe measurable impacts of these cuts.

Report

PxWire Volume 15, Issue 2

The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.